Efficacy of oral micronized progesterone in the treatment of luteal phase defects

G. N. Frishman*, S. C. Klock, A. A. Luciano, J. C. Nulsen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


OBJECTIVE: Vaginal progesterone suppositories are an accepted treatment for infertility attributed to luteal phase defects. Although oral micronized progesterone may be preferable to suppositories for many patients, there are no studies on its use for patients with luteal phase defects. This study evaluated the efficacy of oral micronized progesterone for the treatment of luteal phase defects. STUDY DESIGN: Seven women with luteal phase defects previously corrected by vaginal suppositories were administered oral micronized progesterone (200 mg by mouth three times a day). Endometrial biopsies were performed to evaluate treatment efficacy. Questionnaires were used to assess side effects, including sedation. RESULTS: On oral micronized progesterone, all patients had in-phase endometrial biopsies. Despite complaints of drowsiness, the majority of patients preferred the oral formulation over the vaginal route of administration. CONCLUSION: We conclude that oral micronized progesterone is efficacious in the treatment of luteal phase defects.

Original languageEnglish (US)
Pages (from-to)521-524
Number of pages4
JournalJournal of Reproductive Medicine for the Obstetrician and Gynecologist
Issue number7
StatePublished - Aug 9 1995


  • luteal phase
  • progesterone

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Efficacy of oral micronized progesterone in the treatment of luteal phase defects'. Together they form a unique fingerprint.

Cite this